Abvc Biopharma (ABVC) Current Deferred Revenue (2019 - 2026)
Abvc Biopharma (ABVC) recorded Current Deferred Revenue of $12,600 in Q3 2026, down 84.5% from $81,115 a year earlier and unchanged from the prior quarter.
Powered by 
Analysis
Abvc Biopharma (ABVC) Current Deferred Revenue (2019 - 2026) Analysis & Trends
Starting with Q3 2019, Abvc Biopharma's Current Deferred Revenue history includes 29 quarters.
- Annual Current Deferred Revenue has a five-year compound annual growth rate of 0.9% (FY2020 to FY2025).
- Across earlier years, Current Deferred Revenue came in at $81,115 in FY2024 (+2.0%), $79,500 in FY2023 (+623.7%), $10,985 in FY2022 (unchanged) and $10,985 in FY2021 (-9.0%).
- Quarterly Current Deferred Revenue has ranged from $10,985 in Q4 2021 to $81,115 in Q3 2025 over the past five years.
- On a year-over-year basis, Current Deferred Revenue has declined for four consecutive quarters, with an average decline of 41.2% over the last eight quarters.
- Peak year-over-year performance for Current Deferred Revenue in the last five years was growth of 623.7% in Q3 2023, against a decline of 84.5% in Q4 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $12,600 (Q2 2026), $12,600 (Q1 2026) and $12,600 (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn |
| 10 | Abvc Biopharma | 24.28 Mn | 21.86 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 12,600.00 |
| Jun 30, 2026 | 12,600.00 |
| Mar 31, 2026 | 12,600.00 |
| Dec 31, 2025 | 12,600.00 |
| Sep 30, 2025 | 81,115.00 |
| Jun 30, 2025 | 81,115.00 |
| Mar 31, 2025 | 81,115.00 |
| Dec 31, 2024 | 81,115.00 |
| Sep 30, 2024 | 79,500.00 |
| Jun 30, 2024 | 79,500.00 |
| Mar 31, 2024 | 79,500.00 |
| Dec 31, 2023 | 79,500.00 |
| Sep 30, 2023 | 79,501.00 |
| Jun 30, 2023 | 79,501.00 |
| Mar 31, 2023 | 10,985.00 |
| Dec 31, 2022 | 10,985.00 |
| Sep 30, 2022 | 10,985.00 |
| Jun 30, 2022 | 10,985.00 |
| Mar 31, 2022 | 10,985.00 |
| Dec 31, 2021 | 10,985.00 |
API Access
Abvc Biopharma Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ABVC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "ABVC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ABVC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();